We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Acoustic Separation Improves Stem Cell Transplants

By HospiMedica International staff writers
Posted on 20 Sep 2011
Transplantation of hematopoietic stem cells is an effective treatment for patients with malignant blood diseases. More...
The composition and quality of the transplanted cells are crucial to the outcome. Swedish researchers have now developed a method to improve the quality of the transplanted cells using ultrasound technology for cell separation.

For patients with blood cancer, a blood stem cell transplant is typically the only treatment that can cure the disease. The quality of the transplanted blood stem cells and the choice and composition of the transplanted cells can be crucial.

Current methods of collecting and processing stem cell products leave a lot to be desired. Recent results from Lund University indicate that it may be possible to improve significantly the quality of the blood stem cell product by using a method known as acoustic cell separation. “The method was developed in the field of microtechnology and builds on basic engineering research from Lund University,” explained Prof. Thomas Laurell, research group leader at the faculty of engineering at Lund University (Sweden). The technique is expected to facilitate improvements in the processing of blood stem cells.

Associate professor Stefan Scheding, senior consultant at the department of hematology at Skåne University Hospital and research group leader at the Stem Cell Center at Lund University, is in charge of the preclinical development of the new method, which aims to effectively separate and possibly remove or concentrate cell populations that are normally found in standard blood stem cells products. The first phase has been to demonstrate that the method works, by separating out platelets from stem cell products.

“Our hope is that it will become possible to produce the optimal stem cell product for each individual transplant patient,” said Prof. Scheding. “This would give us a good chance of improving the treatment of patients who would otherwise be at risk of suffering from serious transplant complications, such as graft-versus-host disease and infections. By optimizing the quality of the transplanted cells, it may even be possible to better fight the leukemia cells that remain in the body despite the transplant treatment.”

Related Links:

Lund University



Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
LED Surgical Lamp
ACEMST35/57
Open Stapler
PROXIMATE Linear Cutter
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.